|Bid||66.24 x 900|
|Ask||66.31 x 900|
|Day's Range||66.00 - 66.98|
|52 Week Range||60.23 - 140.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.31|
Legendary venture capital firm Kleiner Perkins Caufield & Byers bought into Redwood City's ARMO BioSciences Inc. in December 2012 when Series A shares sold for $1. It stuck with the company into a January IPO at $17 and now with a $50-per-share buyout by Eli Lilly & Co.
NEW YORK, May 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Voya ...
Tesla Motors Inc (NASDAQ:TSLA) CEO Elon Musk has made amends with investors of his company after a poorly handled earnings call last week sent shares of the electric automaker tumbling. Musk bought 33,000 Tesla shares on Monday in a series of purchases that lifted his indirect ownership of Tesla to just under 33.64 million shares. […]
Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.
For the full year, the company reaffirmed revenue forecasts for its chemotherapy treatment Jakafi and leukemia drug Iclusig, and also increased its estimated non-GAAP research and development costs. It still expects trial results for its graft-versus-host treatment ruxolitinib in the first half of the year. Elsewhere, Regeneron is down 1.9% to $297.86 after Guggenheim's Adnan Butt downgraded the company to Neutral from Buy, following product reports from partner Sanofi (SNY) last week that may "foreshadow a slower-than-forecast ramp." He also warns that cholesterol drug Praluent and arthritis drug Kevzara may not see near-term accelerated growth, while chemotherapy treatment Eylea could face new competition--hence his decision to downgrade the shares until there is "greater pipeline progress." He thinks the stock's fair value is $362.
Incyte Corporation today reports 2018 first-quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company’s development portfolio.
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
Alphabet Inc. ( GOOG), Google's parent company, paid its employees nearly $200,000 last year, placing it in fourth place in terms of median compensation among S&P 500 Index companies that disclose pay. Citing Alphabet, the Wall Street Journal reported that in 2017 it had median pay packages of more than $197,000, which was 18% below Facebook Inc. ( FB) where the median salary was $240,000 in 2017. Excluding the two, which are embroiled in a talent war with other technology companies, the median salary for companies in the S&P 500 was $69,205, noted the Wall Street Journal.
Incyte Corporation announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.
Incyte Corporation announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology annual meeting in Chicago, Illinois from June 1-5, 2018.
NEW YORK, NY / ACCESSWIRE / April 25, 2018 / The markets recent slide continued Tuesday as concerns of rising interest rates continued to plague investors. On Tuesday, the yield on the benchmark on the ...
rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.
Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg dose. Incyte Corp. , a partner on the drug, had its shares drop nearly 5% premarket. The recommendation, made by the FDA's arthritis advisory committee late Monday, was based on concerns about the 4-mg dose's safety and risks relative to its benefits.
INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
NEW YORK , April 20, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation ("Incyte" ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors ...